MannKind’s diabetes drug Afrezza recommended by FDA advisory
The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted 13 to 1 to recommend that MannKind Corp’s (Nasdaq: MNKD) Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
The Committee also voted unanimously (14 to 0) to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. If approved, Afrezza would be the first ultra rapid-acting mealtime insulin therapy available in the USA, noted MannKind.
MannKind ‘s share price more than doubled to $8.46 in extended trading in New York yesterday, having declined 17% to $4.02 on Monday in anticipation of a negative vote by the expert panel. The shares were suspended ahead of the Committee meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze